GDNF and Parkinson disease: On the other hand, the convection improved delivery of AAV2-GDNF in phase-1 clinical study, which is evaluating the efficacy and safety of AAV2-GDNF genetic transfer to treat advanced PD (McFarthing et al., 2019; Fiandaca et al., 2020; Van Laar et al., 2021).